§01 Browse › Retatrutide

Retatrutide

GLP-1/GIP/glucagon triple agonist LY3437943
Research Compound
Cutting

Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptor pathways simultaneously. In phase 2 trials it produced weight loss of approximately 24% of body weight over 48 weeks, exceeding tirzepatide and semaglutide in head-to-head comparisons. The addition of glucagon receptor agonism accelerates lipolysis and energy expenditure beyond what GLP-1 and GIP activation alone produce.

Protocol Why Use It Comparison Safety
Warning
Still in clinical trials; long-term safety data is unavailable · Glucagon agonism increases resting heart rate in some users · Potent appetite suppression requires deliberate protein and electrolyte intake to preserve lean mass
Read This First
Before you plan around Retatrutide, ground the basics.
Retatrutide is easier to misuse when bloodwork, recovery, or category context is skipped.
beginner The Philosophy and Practice of Harm Reduction 9 min read intermediate GLP-1 Receptor Agonists: Semaglutide, Tirzepatide, and Retatrutide 8 min read Intro to Peptides Peptide Reconstitution and Injection Math
Why people use it

Retatrutide is chosen because it looks like the next step beyond Semaglutide and Tirzepatide. It attracts users who want the most aggressive currently discussed pharmaceutical-style fat-loss option and are willing to accept that the real-world safety picture is still early.

Protocol & usage
  • Not commercially available as of 2025; sourced as a research peptide requiring reconstitution.
  • Reconstitute with bacteriostatic water per vendor instructions. Store refrigerated; discard after 30 days once reconstituted.
  • Titrate slowly from a very low starting dose, exactly as with semaglutide or tirzepatide. Nausea is the primary dose-limiting side effect.
  • Once-weekly subcutaneous injection. Rotate injection sites to minimise local irritation.
  • Monitor fasting glucose and heart rate; glucagon receptor agonism may increase resting heart rate meaningfully in some users.
  • Safety data beyond 48-week phase 2 trial windows is not yet available. Long-term effects are unknown.
Timeline & expectations

Expectations should stay disciplined. Early trial results are impressive, but impressive weight loss is not the same thing as clean body-composition improvement. If appetite suppression outruns protein intake, hydration, and training quality, the result can still be a worse physique at a lower bodyweight.

Notes

Use context

Retatrutide is the most aggressive end of the current incretin conversation because it combines GLP-1, GIP, and glucagon receptor agonism. That third pathway is what makes it different. It is also what makes it harder to treat like a simple stronger version of semaglutide or tirzepatide.

The promise is greater bodyweight reduction and more energy-expenditure drive. The cost is a thinner evidence base, more uncertainty around long-term tolerability, and a greater need to pay attention to hydration, resting heart rate, and lean-mass retention while bodyweight drops.

Common mistakes

The main mistake is treating early clinical excitement as mature long-term safety evidence. The second is letting rapid bodyweight loss outpace the user’s ability to preserve muscle, hydration, and performance.

Comparison notes

Compared with Semaglutide and Tirzepatide, retatrutide usually promises more. It also asks the user to tolerate a thinner evidence base, greater uncertainty, and less room to act as though the compound is already fully understood.

Safety & monitoring
Side effects

  • GI upset, higher heart rate, rapid weight-loss pace, and uncertain long-term tolerability

  • More potent appetite suppression than many users can manage intelligently

Monitoring

  • bodyweight trend

  • resting heart rate

  • fasting glucose / HbA1c

Avoid if

  • Users who cannot tolerate aggressive appetite suppression or fast bodyweight change

  • Treating an investigational drug like a routine supplement

Add to Cycle Builder Read: The Philosophy and Practice of Harm Reduction ← Browse